MS Briefs

Risk Tolerance in MS Therapies

Neurology; ePub 2019 Mar 13; Fox, et al


 

In a recent survey, patients with multiple sclerosis (MS) displayed a wide range of risk tolerance (RT) to MS therapies. People with MS from the North American Research Committee on Multiple Sclerosis Registry’s online cohort and the National Multiple Sclerosis Society were invited to complete a questionnaire on tolerance to real-world risks associated with a hypothetical therapy. Multiple risk levels were presented, including skin rash, infection, kidney injury, thyroid injury, liver injury, and progressive multifocal leukoencephalopathy (PML). Researchers found:

  • Both PML and kidney injury had the lowest RT; thyroid and infection risk had the highest tolerance.
  • Men, younger individuals, and those with greater disability reported a higher tolerance to all risk scenarios.
  • Participants currently taking an MS therapy reported higher tolerance vs those not taking any therapy.

Fox RJ, Cosenza C, Cripps L, et al. A survey of risk tolerance to multiple sclerosis therapies. [Published online ahead of print March 13, 2019]. Neurology. doi:10.1212/ WNL.0000000000007245.

Recommended Reading

Genetic signature helps identify those at risk of MS
ICYMI Multiple Sclerosis
New data bolster latitude’s association with MS prevalence
ICYMI Multiple Sclerosis
Optical coherence tomography emerging as a promising biomarker for MS
ICYMI Multiple Sclerosis
Study eyes serious adverse events from long-term rituximab use in MS
ICYMI Multiple Sclerosis
Smartphone technology helps to detect, track eye changes in MS
ICYMI Multiple Sclerosis
Expert calls for more ‘ethnocentric’ research in MS
ICYMI Multiple Sclerosis
Interview with John Corboy, MD, on discontinuing disease modifying therapy in elderly patients with MS
ICYMI Multiple Sclerosis
Study launched to further evaluate the central vein sign in MS
ICYMI Multiple Sclerosis
MS researchers aim to build MRI diagnostic portfolio beyond the central vein sign
ICYMI Multiple Sclerosis
30-Day Readmissions in Multiple Sclerosis
ICYMI Multiple Sclerosis